TRVN - Trevena, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.7000
+0.1100 (+6.92%)
At close: 4:00PM EDT

1.7000 0.00 (0.00%)
After hours: 7:50PM EDT

Stock chart is not supported by your current browser
Previous Close1.5900
Open1.6100
Bid1.6900 x 1800
Ask1.7000 x 27000
Day's Range1.5900 - 1.7100
52 Week Range0.4600 - 1.9050
Volume2,737,363
Avg. Volume2,819,422
Market Cap182.208M
Beta (5Y Monthly)2.74
PE Ratio (TTM)N/A
EPS (TTM)-0.2720
Earnings DateAug. 05, 2020 - Aug. 10, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Company News for June 3, 2020
    Zacks

    Company News for June 3, 2020

    Companies in the news are: DCI, TENX, TRVN, BHTG

  • GlobeNewswire

    Trevena Announces Advancement of Oliceridine Clinical Development in China by Jiangsu Nhwa Pharmaceutical Co.

    Trevena, Inc. (TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the Company’s partner in China has been approved by the Chinese National Medical Products Administration (NMPA) to initiate clinical trials for IV oliceridine, Trevena’s lead investigational asset for the management of moderate-to-severe acute pain. Jiangsu Nhwa holds an exclusive license agreement for the development and commercialization of oliceridine in China.

  • GlobeNewswire

    Trevena Announces Collaboration with Imperial College London to Evaluate TRV027 in COVID-19 Patients

    Trevena, Inc. (TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced it has entered into a collaboration with Imperial College London to evaluate the potential of TRV027, a novel AT1 receptor selective agonist, to treat acute lung injury contributing to acute respiratory distress syndrome (ARDS) in COVID-19 patients. ARDS is a major complication leading to mortality associated with COVID-19.

  • Is Trevena (TRVN) Outperforming Other Medical Stocks This Year?
    Zacks

    Is Trevena (TRVN) Outperforming Other Medical Stocks This Year?

    Is (TRVN) Outperforming Other Medical Stocks This Year?

  • GlobeNewswire

    Trevena Reports First Quarter 2020 Results

    Trevena Reports First Quarter 2020 ResultsFDA review of oliceridine NDA ongoing; PDUFA date August 7, 2020 IND filing for novel S1P modulator (TRV045) in 1H 2021; ongoing.

  • Has Trevena, Inc.
(TRVN) Outpaced Other Medical Stocks This Year?
    Zacks

    Has Trevena, Inc. (TRVN) Outpaced Other Medical Stocks This Year?

    Is (TRVN) Outperforming Other Medical Stocks This Year?

  • GlobeNewswire

    Trevena to Release First Quarter 2020 Financial Results on May 7, 2020

    CHESTERBROOK, Pa., May 01, 2020 -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients.

  • GlobeNewswire

    Trevena Announces Publication of Comprehensive Review of Oliceridine Data

    Trevena, Inc. (TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the publication of a review of the clinical and nonclinical data for oliceridine in Drugs of Today. The publication is titled “Oliceridine, a G protein-selective ligand at the μ-opioid receptor, for the management of moderate to severe acute pain”, with lead author Tong J. Gan, M.D., Department of Anesthesiology at Stony Brook Medicine (DOI: 10.1358/dot.2020.56.4.3107707). “I am pleased to have the opportunity to provide a comprehensive overview of the data we have amassed over the entire oliceridine development program from over 1,800 individuals,” said Mark A. Demitrack, M.D., Senior Vice President and Chief Medical Officer of Trevena, Inc. “This monograph is the latest addition to the compelling body of peer-reviewed published literature for oliceridine, and summarizes the novel characteristics that make it a potentially differentiated treatment option for moderate-to-severe acute pain in hospital settings.”

  • Thomson Reuters StreetEvents

    Edited Transcript of TRVN earnings conference call or presentation 12-Mar-20 12:00pm GMT

    Q4 2019 Trevena Inc Earnings Call

  • GlobeNewswire

    Trevena Reports Fourth Quarter and Full Year 2019 Results

    PDUFA date of August 7, 2020 for IV oliceridine; FDA considers NDA resubmission complete Initiated proof-of-concept studies for acute migraine (TRV250) and opioid use disorder.

  • GlobeNewswire

    Trevena to Report Fourth Quarter and Full Year 2019 Results on March 12, 2020

    CHESTERBROOK, Pa., March 05, 2020 -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients.

  • GlobeNewswire

    Trevena Announces FDA Has Set PDUFA Date of August 7, 2020 for Oliceridine

    Trevena, Inc. (TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the resubmitted New Drug Application (NDA) for IV oliceridine, the Company’s lead investigational asset for the management of moderate-to-severe acute pain.

  • GlobeNewswire

    Trevena Appoints Scott Applebaum as Chief Legal and Compliance Officer and SVP of Regulatory Affairs

    Trevena, Inc. (TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the appointment of Scott Applebaum as Chief Legal and Compliance Officer and Senior Vice President of Regulatory Affairs. Mr. Applebaum comes to the Company with over 20 years of experience in a variety of senior leadership roles at both large and small companies at various stages of development and commercialization in the biopharmaceuticals sector.

  • Trevena (TRVN) Resubmits NDA for Pain Drug Oliceridine to FDA
    Zacks

    Trevena (TRVN) Resubmits NDA for Pain Drug Oliceridine to FDA

    Trevena (TRVN) resubmits the NDA to the FDA for IV oliceridine for the management of moderate-to-severe acute pain.

  • GlobeNewswire

    Trevena Resubmits New Drug Application for Oliceridine

    Trevena, Inc. (TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for IV oliceridine, the Company’s lead investigational product for the management of moderate-to-severe acute pain. The Company anticipates a six-month review period by FDA.

  • GlobeNewswire

    Trevena to Present at the 2020 BIO CEO & Investor Conference

    CHESTERBROOK, Pa., Feb. 05, 2020 -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients.

  • How Much Are Trevena, Inc. (NASDAQ:TRVN) Insiders Spending On Buying Shares?
    Simply Wall St.

    How Much Are Trevena, Inc. (NASDAQ:TRVN) Insiders Spending On Buying Shares?

    We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...

  • GlobeNewswire

    Trevena Announces Initiation of Proof-of-Concept Study for TRV734 for Potential Treatment of Opioid Use Disorder

    Trevena, Inc. (TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the initiation of a proof-of-concept study for TRV734, the Company’s novel mu-opioid receptor selective agonist. TRV734 is currently being evaluated as a potential maintenance therapy for opioid use disorder. The study is funded by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health.

  • GlobeNewswire

    Trevena Presents Phase 1 Data on TRV250 for Acute Migraine at American College of Neuropsychopharmacology 2019 Annual Meeting

    Trevena, Inc. (TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced a poster presentation at the 58th Annual Meeting of the American College of Neuropsychopharmacology (ACNP), in Orlando, FL. The poster presentation featured results from a Phase 1 first-in-human study that evaluated the safety, tolerability, and pharmacokinetics (PK) of TRV250, the Company’s novel G protein-selective delta-receptor agonist being developed for the acute treatment of migraine. TRV250 was well-tolerated up to 30 mg, with a PK profile appropriate for an acute migraine therapy.

  • GlobeNewswire

    Trevena Announces Publication of Results from Phase 3 “Real World” Safety Study for Oliceridine in The Journal of Pain Research

    The results highlight the safety and tolerability of oliceridine in the management of moderate-to-severe acute pain in a variety of surgical / medical settings and patient populations. The publication, “ATHENA: A Phase 3, Open Label Study of the Safety and Effectiveness of Oliceridine (TRV130), a G-Protein Selective Agonist at the µ-Opioid Receptor, in Patients with Moderate to Severe Acute Pain Requiring Parenteral Opioid Therapy” with investigator and lead author, Sergio Bergese, M.D., Department of Anesthesiology, School of Medicine, Stony Brook University, is available online on Dove Medical Press.

  • GlobeNewswire

    Trevena Announces Publication of Results from Special Population Studies for Oliceridine

    No dose adjustments required for patients with renal impairment or patients with mild / moderate hepatic impairment CHESTERBROOK, Pa., Nov. 20, 2019 -- Trevena, Inc..

  • GlobeNewswire

    Trevena to Present at the Stifel 2019 Healthcare Conference

    CHESTERBROOK, Pa., Nov. 18, 2019 -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients.

  • Thomson Reuters StreetEvents

    Edited Transcript of TRVN earnings conference call or presentation 4-Nov-19 1:30pm GMT

    Q3 2019 Trevena Inc Earnings Call

  • GlobeNewswire

    Trevena Reports Third Quarter 2019 Results and Topline Data From Multi-Dose Healthy Volunteer QT Study

    Company expects to resubmit NDA for oliceridine in Q1 2020  Acute migraine proof-of-concept study for TRV250 initiated  Company to host conference call at 8:30 a.m. EST.

  • GlobeNewswire

    Trevena Announces Presentations at the American Society of Anesthesiologists 2019 Annual Meeting

    Trevena, Inc. (TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) conditions, today announced four presentations at ANESTHESIOLOGY® 2019, the national conference for the American Society of Anesthesiologists, held at the Orange County Convention Center in Orlando, Florida, October 19-23.  The presentations included one oral presentation and three posters, all of which discussed the safety profile of oliceridine. “IV opioids remain an effective treatment option for physicians in managing moderate-to-severe acute pain following surgery.